Dr. Ahmad Tarhini on Ipilimumab vs Interferon- α2b for Resected High-Risk Melanoma

Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III  United States Intergroup E1609 trial, presented at ASCO 2019.

Source: CancerNetwork - June 12, 2019 Category: Cancer & Oncology Authors: Ahmad A. Tarhini, MD, PhD Source Type: news